July 2018 by Lindsay McKenna Pharmacokinetic (PK) and safety studies in children continue to progress, producing a steady flow of data (Table 2). Yet the translation of research and development gains into policy and access for children with tuberculosis (TB)…
GCTA, TAG, and DR-TB STAT developed this letter template to help activists to call for bedaquiline-based, injectable-free regimens in their countries. Please download this template letter here and use it in your country to advocate for the best care possible for people with drug-resistant TB.
In advance of the first-ever United Nations High-Level Meeting on Tuberculosis (TB), a new brief from Treatment Action Group (TAG) — Funding for TB Research: Recent Momentum Must Inspire Bold Commitments — shows that global funding for TB research and development (R&D) reached a new high of USD $767.8 million in 2017.
This document (not a TAG publication) presents an overview of paediatric TB research efforts already underway and their limitations; and highlights priorities for future research initiatives in epidemiology, basic science, prevention, diagnosis, treatment and operational research.
The Global Tuberculosis Community Advisory Board (TB CAB) and Treatment Action Group (TAG) welcome the new World Health Organization (WHO) recommendation of injectable-free regimens for the treatment of rifampicin- and multidrug-resistant tuberculosis (RR/MDR-TB).
Treatment Action Group (TAG), the Global Tuberculosis Community Advisory Board (CAB), the DR-TB Scale-Up Treatment Action Team (DR-TB STAT), and TB Proof hosted a webinar on Thursday, August 16, 2018 to discuss the evidence for and importance of using bedaquiline-based,…
In response to the reopening of negotiations on the TB High-Level Meeting (HLM) political declaration, a coalition of U.S.-based civil society stakeholders have submitted a letter to U.S. Ambassador to the UN, Nikki Haley, urging a diplomatic solution to the contentious provisions on access to medicines.
At the TB 2018 pre-conference held on Sunday 22 July 2018, before the International AIDS Conference in Amsterdam, activists from around the globe called on their countries, development partners, and donors, to end the unacceptable death rates caused by TB in people living with HIV by immediately scaling up the use of TB LAM testing.
Treatment Action Group (TAG) submitted comments to the National Institute of Allergy and Infectious Diseases (NIAID) at the U.S. National Institutes of Health (NIH) in response to a public request for information (RFI) to inform NIAID's Tuberculosis Strategic Plan on supporting TB research and development (R&D).
Treatment Action Group (TAG), NASTAD (National Alliance of State & Territorial AIDS Directors) and HIVMA (HIV Medicine Association join together in submitting collaborative comments today in response to the Department of Health and Human Services (HHS) public request for information (RFI) on the agency’s Blueprint to Lower Drug Prices and Reduce Out-of-Pocket Costs.